MiMedx Group (MDXG) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings or view top-rated stocks.

2 brokers have issued 1-year target prices for MiMedx Group's stock. Their MDXG share price forecasts range from $7.00 to $9.50. On average, they expect the company's stock price to reach $8.25 in the next year. This suggests a possible upside of 45.8% from the stock's current price.
View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts.

MiMedx Group's stock was trading at $2.78 at the beginning of 2023. Since then, MDXG shares have increased by 103.6% and is now trading at $5.66.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our MDXG earnings forecast.

MiMedx Group, Inc. (NASDAQ:MDXG) announced its quarterly earnings results on Tuesday, May, 2nd. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03. The business earned $71.68 million during the quarter, compared to the consensus estimate of $63.48 million.

ETFs with the largest weight of MiMedx Group (NASDAQ:MDXG) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU) and

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.88%), State Street Corp (3.24%), Paradigm Capital Management Inc. NY (2.98%), Geode Capital Management LLC (1.90%), Richmond Brothers Inc. (1.52%) and Federated Hermes Inc. (0.82%). Insiders that own company stock include Mark Graves, Peter M Carlson, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends.

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDXG stock can currently be purchased for approximately $5.66.

MiMedx Group (NASDAQ:MDXG) has a market capitalization of $654.30 million and generates $267.84 million in revenue each year. The company earns $-30,200,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

The company employs 811 workers across the globe.

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The official website for the company is www.mimedx.com. The company can be reached via phone at (770) 651-9100, via email at investorrelations@mimedx.com, or via fax at 678-384-6741.